PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute ( | for form | 1449A/PTO |  |
|--------------|----------|-----------|--|
|              |          |           |  |

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 Sheet of

| Complete if Known      |                   |  |  |
|------------------------|-------------------|--|--|
| Application Number     | 10/079,703        |  |  |
| Filing Date            | February 20. 2002 |  |  |
| First Named Inventor   | Craig Anderson    |  |  |
| Art Unit               | 1642 1/2/4        |  |  |
| Examiner Name          | SYIVA'NK          |  |  |
| Attorney Docket Number | 1/1282            |  |  |

| U.S. PATENT DOCUMENTS |   |   |                  |   |   |  |
|-----------------------|---|---|------------------|---|---|--|
| Examiner<br>Initials  |   | Document Number Number - Kind Code <sup>2</sup> (if known | Publication Date | Name of Patentee or . Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   | -   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  | N 222 2 - 1                                       |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       | i | US-   |                  |   |   |  |
|                       |   | us-   |                  |   |   |  |
|                       |   | US-   |                  |   |   |  |
|                       | i | US-   |                  |   |   |  |
|                       |   | US-   | -                |   |   |  |
|                       | i | US-   |                  |   |   |  |

|                      | FOREIGN PATENT DOCUMENTS |   |                                |  |   |    |  |  |
|----------------------|--------------------------|---|--------------------------------|--|---|----|--|--|
| Examiner<br>Initials | Cite<br>No. <sup>1</sup> | Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T6 |  |  |
| Ds                   |                          | WO-99/65500-A1  | 12/23/1999                     | Bristol-Myers Squibb                               |   |    |  |  |
| 175                  |                          | EP-0629408-A1   | 12/21/1994                     | Merck et al  |   |    |  |  |
|                      |                          |   |                                |  |   |    |  |  |
|                      |                          |   |                                |  |   |    |  |  |
| ļ                    |                          |   |                                |  | **************************************  |    |  |  |
|                      |                          |   |                                |  |   |    |  |  |
|                      |                          |   |                                |  |   |    |  |  |

Date Examiner Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

other the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB
outrol number. ontrol number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

| Complet if Known       |                   |  |  |  |
|------------------------|-------------------|--|--|--|
| Application Number     | 10/079,703        |  |  |  |
| Filing Date            | February 20, 2002 |  |  |  |
| First Named Inventor   | Craig Anderson    |  |  |  |
| Group Art Unit         | /////             |  |  |  |
| Examiner Name          | SPIVACK           |  |  |  |
| Attorney Docket Number | 1/1282            |  |  |  |

| OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS |              |   |                |  |  |
|---|--------------|---|----------------|--|--|
| Examiner<br>Initials                            | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |  |  |
| B   |              | YUSUF, SALIM; From the HOPE to the ONTARGET and the TRANSCEND Studies: Challenges in Improving Prognosis; The American Journal of Cardiology; 2002; 18A - 25A; V. 89; No. 2A.   |                |  |  |
| 3   |              | WEBER, MICHAEL; The 24-Hour Blood Pressure Pattern: Does it Have Implications for Morbidity and Mortality?; The American Journal of Cardiology; 2002; 27A-33A; V. 89; No. 2A  |                |  |  |
|   |              |   |                |  |  |
|   |              |   | <u>.</u>       |  |  |
|   |              |   |                |  |  |
|   |              |   |                |  |  |
|   |              |   |                |  |  |
|   |              |   |                |  |  |
|   |              |   | ,              |  |  |
|   |              |   |                |  |  |
|   |              |   | _              |  |  |
|   |              |   |                |  |  |
|   |              |   |                |  |  |

| Examiner<br>Signature | Phullis | $\mathcal{L}$ | PWACK | Date<br>Considered | 7/18/03 |
|-----------------------|---------|---------------|-------|--------------------|---------|
|                       |         |               | *     |                    |         |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.